Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi ...
Silexion Therapeutics Corp Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing ...
CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, announced significant preclinical results for their new drug candidate ...
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...
CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, announced significant preclinical results for their new drug candidate ...
Silexion Therapeutics Corp. announced the immediate exercise of outstanding warrants to purchase 2,221,523 ordinary shares at an exercise price of $1.35 per share, expected to yield approximately ...
NEW YORK--(BUSINESS WIRE)--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with ...
SIL-204 reduced tumor growth by ~50% and caused complete necrosis in ~50% of human pancreatic tumors in mice models with G12D mutations. A single systemic dose of SIL-204 sustained effective drug ...
New preclinical findings provide validation for Silexion's new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback